Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- Newsletter 43/2026 October 25, 2026
- Phase 3 DASL-HiCaP: Darolutamide Reduces Metastasis Risk in High-Risk Prostate Cancer October 24, 2026
- UPDATE: PROTEUS Substudy Shows Improved Event-Free Survival With Perioperative Apalutamide October 24, 2026
- UPDATE: Bavdegalutamide Shows Stronger Activity in Prostate Cancers With Specific AR Mutations October 23, 2026
EVO 2 AI: Redefining Genetic Engineering
/in Artificial Intelligence/by MaxENV105 to Reverse Resistance to ADT and ARSI
/in Clinical Trial, Metastatic, Phase 2/by MaxUpdate: 67Cu-SAR-bisPSMA for mCRPC Has Been Fast-Tracked by FDA
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxA New Compound Looks Promising for Bone Metastasis
/in Not PCa related, Preclinical Research/by MaxAI-Powered Drug Repurposing Advances: Using Artificial Intelligence to Find New Cancer Treatments
/in Artificial Intelligence/by MaxASCO GU 2025: Combination Therapy with Cabozantinib and Atezolizumab Shows Promise for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxNew Study Reveals Key Factors That Influence How Quickly Prostate Cancer Becomes Resistant to Hormone Therapy
/in Retrospective studies/by MaxASCO GU 2025: Continuous ADT Remains Superior to Intermittent Therapy in Metastatic Hormone-Sensitive Prostate Cancer
/in Retrospective studies/by Max